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Summary 
This mini-review presents the research carried out within the context of two of the main 
hypotheses of the aetiology of coeliac disease. The enzymopathic hypothesis of the disease 
has been placed clearly as the underlying deficiency causing increased levels of toxic 
peptides, while the immunological hypothesis has been implicated in the pathogenesis of 
the disorder as the result of the action of undigested peptides in the small intestine. 
As a consequence, we are proposing a unified hypothesis of coeliac disease, which takes 
into account the actions of these undigested peptides through their direct cytotoxicity and 
their immunoactivity. At the same time, work aimed at defining some of these biologically 
active peptides, which could be said to be involved in the aetiopathogenesis of coeliac 
disease, will be reported. 
The review also focusses on the use of enzyme therapy for management of the disease, 
which when used in conjunction with the gluten-free diet, offers a safeguard against 
damage to the small intestine caused by small amounts of gluten. 
Key words: coeliac disease, enzyme therapy, gliadins, gluten, disease mechanisms, 
peptidases. 
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l.Introduction 
Coeliac disease (CD) has been described as an intolerance to certain proteins of wheat, 
barley and rye which lead to damage of the finger-like projections of the small intestine. 
Symptoms range from minor gastrointestinal complaints to severe malabsorption of 
nutrients caused by reduction in the absorptive surface of the duodenum and jejunum 
(Duggan,1997). At the cornerstone of treatment is dietary avoidance ofthese cereals, but 
there are difficulties because ofthe lack of clear advice on the food being gluten-free, 
particularly in situations where the food is prepared by people without a detailed 
knowledge of the ingredients and where the sufferers are young in years. If left untreated, 
serious consequences of malabsorption such as osteoporosis and anaemia, as well as 
lymphomas can occur (Duggan, I 997). Early work by Frazer et al. (1959) suggested that 
the cause of the disease was an enzyme deficiency which allowed the accumulation of 
toxic peptide residues in the small intestine. They showed that peptic-tryptic digests of 
gluten still retained the toxicity demonstrated previously in whole gluten by Anderson et 
al.(l952). The use ofpeptic-tryptic-pancreatinic (PTP) digests of wheat gliadin (as would 
be physiological) was reported by Bronstein et al.(l966) and showed that toxicity was 
retained, enabling the study oflow molecular weight oligopeptide mixtures (average 
molecular weight 1500 daJtons) essentially free of polypeptides. This digestion technique 
was taken up by Cornell and Townley (l973a) who showed that one ion exchange fraction 
ofthis digest (Fraction 9) was digested to a lesser extent by duodenal mucosa from coeliac 
patients in remission than the other fractions of the digest. Mucosal digestion by the 
normal controls showed no such difficulties in digestion. Furthermore, Fraction 9 was 
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shown to be much more toxic than the other fractions in in vitro cultures of biopsy tissue 
from patients with active disease (Townley et aI., 1973) and by in vivo studies based on 
urinary xylose excretion (Cornell and Townley,1974). Serum antibodies were also 
directed at Fraction 9 and were higher than those in controls (Cornell, 1974). 
An important milestone in this research was reached with the publication of the amino 
acid sequence of wheat A-gliadin by Kasarda et al.(1984), because this led to De Ritis et 
al.(1988) showing that certain amino acid sequences, called motifs, were associated with 
toxicity. They showed that PSQQ and QQQP were two such motifs present in peptides 
shown to be toxic in vitro. Since then, most of the in vitro and in vivo studies have 
confirmed the importance of one or both of these motifs (Wieser,1996). 
Over the years, it seems that the symptoms associated with coeliac disease have changed 
from the classical rather severe gastrointestinal types to more covert ones such as fatigue, 
lethargy, depression and mild gastrointestinal ones such as stomach. pain, bloating and the 
like. These symptoms are often associated with other illnesses and have contributed to the 
present problems of diagnosis, with the result that many patients are only diagnosed late in 
life, after malabsorption sequelae have become apparent. 
It is still accepted that certain proteins of wheat, barley and rye are known to be the 
causative agents in CD and that some coeliacs are intolerant of oats (Cornell,1996). More 
is now known about the toxicity of U-, ~- and y- gliadins of wheat and the corresponding 
prolamins called hordeins (barley), secalins (rye) and avenins (oats), particularly in regard 
to peptides with certain sequences of amino acids which may be implemented in this 
toxicity. Glutenin proteins have not been studied as extensively as have the gliadins but 
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they account for some of the toxicity of gluten. 
It is also accepted that the disease is underdiagnosed even in countries like USA and 
Australia, and that the likely incidence of the disease is more likely to be about 1 in 250, 
based on figures from Europe, where there is more emphasis on screening school children 
using immunologic tests which measure antibody levels to tissue transglutaminase (tTG). 
Up until now, the only form of treatment has been exclusion of gluten from the diet. 
However, a large majority of patients find it difficult to completely exclude gluten. 
2. The hypotheses of the cause of coeliac disease 
Several hypotheses have been proposed to account for the susceptibility of certain 
individuals to CD and these have been reviewed from time to time (Auricchio et a!., 
1985; Cornell, 1996). Two main hypotheses have remained the subject of research viz., 
The Enzymopathic Hypothesis and the Immunologic Hypothesis. The first has been 
attributed to Frazer et al.(l959), and the second to Falchuk and Strober (1974). A third 
hypothesis relating to a defect in the permeability of the intestinal mucosa in CD 
(Bjarnason and Peters,1983) has also gained some support from recent work, which is 
discussed under Section 4. 
Cornell and Stelmasiak now propose that these hypotheses can be unified, whereby the 
aetiology of the disease, embracing a peptidase deficiency, can be combined with the 
immunology ofthe disease, which is known to be responsible for much of the 
pathogenesis of the disease. Added to this assertion is direct cytotoxicity, which also 
damages tissue. The new hypothesis could thus be called a Unified Theory of the 
Mechanism of Coeliac Disease. 
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3.Progress through synthetic peptides 
Significant progress in the understanding of mucosal digestion of gliadin peptides in CD 
has been made possible by the use of synthetic peptides based on the known A-gliadin 
structure (Kocna et a1.1991). Using in vitro techniques based on digestion of these 
peptides by mucosal homogenates from patients with CD in remission, comparisons with 
digestion by mucosa from normal individuals showed that higher amounts of toxic peptide 
residues remain from coeliac mucosal digestion (Cornell and Rivett,1995; Cornell 1998). 
The foetal chick assay of Mothes et al.(1985) which was the main assay used, correlates 
well with those of human tissue in culture. Thus, defective digestion is at the core of the 
new theory, but needs to be coupled with pathogenetic mechanisms and cytotoxicity in 
order to explain the processes causing tissue damage. Kocna et al.(l991) used synthetic 
peptides based on the A-gliadin structure to verifY this work, evaluating toxicity by means 
of the foetal chick assay (Mothes et al.,1985). An insight into the toxicity of Fraction 9 
came from HPLC studies, which showed that the toxicity was due to both a tyrosine -
containing peptide corresponding to residues 75-86 of A-gliadin and to a serine -
containing peptide corresponding to residues 6-19 ( Cornell et aI., 1992). Working with 
the 6-19 peptide, using an amino acid deletion technique, it was shown that the 
octapeptide 12-19, of structure NPSQQQPQ, containing the motifs PSQQ and QQQP in 
overlapping sequences, was toxic, reinforcing the view that residual octapeptide 
sequences of this type are large enough to retain toxicity, whereas the hexapeptide 13-18 
is not (Cornell and Mothes,1993;1995). 
These in vitro techniques based on digestion of synthetic peptides by remission coeliac 
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mucosa were valuable in that they not only pointed to a deficiency in digestion by the 
remission coeliac mucosa but they also indicated the types of residual peptides, such as 
peptide 12-19 above. The studies also showed that residues of peptides remaining after 
digestion of the toxic peptides from the tyrosine-containing peptide could be toxic. For 
example,the coeliac mucosal digestion of peptide 75-86, RPQQPYPQPQPQ, resulted in 
major amounts of residues of the active octapeptide 77-84 (QQPYPQPQ), compared 
against normal mucosal digestion. These separate studies both showed that the amounts of 
undigested residues from the two types of pep tides were much higher with the remission 
coeliac patients than with the normal controls under the same conditions. 
The serine-containing peptides ( especially peptide 11-19) displayed very potent 
cytotoxicity in the foetal chick assay (Cornell and Mothes, 1995) whereas, the tyrosine-
containing peptides were much more immunogenic (Cornell et.a1.1994). The significance 
of the PSQQ motif in cytotoxicity has been reinforced by the in vivo toxicity of peptide 
206-217, LGQGSFRPSQQN, where the only recognised toxicity motifis PSQQ 
(Mantzaris and Jewell,1991). 
The peptide 31-49 has also been shown to be toxic in vivo, which is significant in that it 
contains both the QQQP and QQPY motifs in its sequence LGQQQPFPPQQPYPQPQPF. 
The QQPY motif is likely to be the one conferring immunogenicity. 
Other immunoreactive peptides have been reported, such as peptide 57-73 of A-gliadin 
with residues 69 and 73 transposed ( Anderson et al.,2000), and the 33-mer peptide 
corresponding to residues 57-89 from 0.-2 gliadin (Shan et al.,2002). However, both these 
peptides lack the PSQQ and QQQP motifs associated with toxicity and their activity may 
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depend on the fact that they are both tyrosine-containing peptides. Only the latter peptide 
has the QPYP motif common to all three coeliac-toxic cereals (Mc Lachlan et aI., 2002). 
Auricchio points out the need to differentiate between the toxic and the immunoactive 
peptides, as they are not necessarily the same. He cites, for example, the A-gliadin 
peptide 56-68, a dominant epitope for coeliac intestinal CD4+ T cells (McAdam and 
Sollid, 2000) which is not able to cause damage in vitro to the intestine of coeliac patients 
(De Ritis et al. 1988). Therefore, it has been suggested that non-immunomediated 
cytotoxity of gliadin peptides on the small intestine might also be involved in the 
pathogenesis of CD, which is supported by gliadin peptides having toxic action on foetal 
rat jejunum but not on mature jejunum (Auricchio et aI., 1984). 
Secondary structural differences in the toxic serine-containing peptides, which favour an 
u- helical structure and the tyrosine-containing peptides, which have a high J3 -turn 
content, are consistent with the different types of toxicity displayed (Cornell and Wills-
Johnson, 2000). A 20-mer peptide from the N-terminal region of an avenin, with strong 
reactivity to anti-gliadin antibodies in coeliac sera was also shown to have a high J3 -turn 
content by circular dichroism (Alfonso et al,1998). Thus, a role for J3 - turn motifs in the 
recognition of these antibodies was suggested and the presence of the QQQP motif 
pointed to its potential toxicity. 
The data presented so far provide evidence for defective mucosal digestion in remission 
coeliac small intestinal mucosa and point to the lack of a peptidase in coeliac mucosa 
which is required to digest certain sequences of amino acids, including the 4-mer motifs 
PSQQ, QQQP and QQPY, as component parts of mainly octapeptides (Cornell,1998). 
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This particular peptidase is present in normal small intestinal mucosa, but is obviously 
deficient in remission coeliac mucosa, and appears to be necessary for disrupting these 
motifs. There is the possibility of a deficiency of more than one type of peptidase. 
Coupled with proteomics, studies ofthe motifs associated with toxicity will help to define 
toxic peptides in cereals other than wheat.Already, it has been shown that extended motifs 
such as QQPYP, PQQPY and QQQPFP are common to wheat, badey and rye (Mc 
Lachlan et ai., 2002) and are all present in the toxic peptide 31-49 of wheat A-gliadin 
(Sturgess et ai.,1994). 
4.Immunological aspects oftissue damage 
The evidence for damage to tissue as the result of immunological mechanisms is 
overwhelming but the evidence that it represents an aberrant reaction as a result of an 
abnormal presentation of gliadin is much less convincing (Biagi et ai., 1999). We therefore 
opt for the concept that these mechanisms only operate as the result of a build-up of 
partially digested peptides which are capable of inducing an immune response which 
could depend upon prior cytotoxic action. The common modern view of the 
immunological mechanism is that HLA class II molecules in antigen - presenting cells 
expose processed peptides to immunocompetent T-cells which initiate the pathogenesis of 
the disease (Maki 1997). On presentation of these epitopes, the T-lymphocytes respond 
by releasing cytokines which elicit changes in small intestinal cells through an 
inflammatory response. These processes damage enterocytes and other cells in the gut. 
The T-cell mediated response in susceptible individuals occurs because of recognition of 
specific peptides by certain T-cells when presented to DQ2 and DQ8 molecules on the 
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surface ofthese cells. Potentiation of binding, and hence activity, by tissue 
transglutaminase reacting with specific glutamine residues in the gliadin fragments can 
bring about autoimmune mechanisms ( Schuppan and Hahn,2002). 
Vader et al.(2002), showed that gluten-specific T-cell responses in HLA-DQ2 positive 
adult coeliac patients are directed at multiple peptides derived from gliadin and glutenin. 
The responses of some of these peptides were not always enhanced by tTG. The authors 
made the point that when tissue damage progresses, the release of cytoplasmic tTG could 
enhance the gluten-specific response to the strongest binding peptides. 
There has been an interest recently in mechanisms which could account for increased 
epithelial permeability of the small intestine and resulting elevated levels of antigen 
presentation (Monsuur et a!., 2005). The authors attributed this increased permeability to 
an impairment of the intestinal barrier through a myosin variant, IXB, and suggested it 
could be a primary defect. Another mechanism of increased permeability has been 
suggested by Drago et a!. (2006) who found that when intestinal biopsies from coeliac 
patients in remission were exposed to luminal gliadin, a sustained release of zonulin was 
observed, together with an increase in intestinal permeability, which was blocked by a 
zonulin antagonist. Controls from individuals without CD showed a limited zonulin 
release but the increase in intestinal permeability was much smaller. This diminished effect 
could be due to more efficient digestion of the gliadin by the normals but the answers to 
these questions regarding permeability mus await the outcome of further experiments 
aimed at defining whether these data represent primary defects or susceptibility factors. In 
this respect, experiments showing the effects of a gluten-free diet would be enlightening. 
10 
With further regard to pathogenesis, the CD4+ gluten-sensitive T-lymphocytes mentioned 
previously, may represent only part of the mechanism of pathogenesis because peptide 31-
49 of A-gliadin is toxic in vivo (Sturgess et aI., 1994) yet it produces no small intestinal T-
cell response. Even so, a monoclonal antibody to this peptide has been produced ( Ellis et 
al.,1998). 
Although most patients with coeliac disease carry the risk alleles encoding the HLA-
DQ2, it should not be assumed that this is the only condition for manifestation of CD. 
Certainly, the genetic association of the disease is evident from these types of studies, but 
it must be remembered that the prevalence ofHLA-DQ2 is high (about 25%) in the 
Northern European population, suggesting that additional genes are probably involved in 
CD (Duggan, 1997). As the incidence of CD is less that 1 % in such a population, more 
specific factors, probably non-HLA related genes, are possibly involved (Maki,1997). 
We would maintain that these reactions occur because, in coeliacs, the concentration of 
undigested peptides is higher due to defective digestion of specific gliadin fragments. 
These fragments are the triggers initiating direct cytotoxicity and all the aforementioned 
reactions. Thus, whether we have high concentrations of the cytoxic serine-containing 
peptides or the immunoactive tyrosine-containing peptides , complete digestion of both 
these types of pep tides would prevent the pathogenesis of the disease. No such damaging 
reactions occur in normal individuals because digestion of the gluten peptides is much 
more complete. The aetiology of CD shares many similarities with dermatitis 
herpetiformis, where the skin is also affected. However, both are quite different from 
wheat allergy. 
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5. Successful iuterveutiou -Euzyme Therapy 
Early studies showed that pre-treatment of gluten with crude papain reduced the toxicity 
of the untreated gluten to coeliac patients, as assessed by faecal fat determinations 
(Messer et aI., 1964). This reduction was not evident when pure papain was used. 
Subsequently, detoxification was attributed to an enzyme called glutamine 
cyclotransferase. The enzyme attacks N-terminal glutamine residues in gluten digests 
forming N-pyrrolidone carboxylyl peptides, which appear to be much less toxic. 
The first example of the application of enzyme therapy was by Messer and Baume (1976). 
Their approach was to attenuate the symptoms of CD in a patient by using the crude 
papain in an enterically coated tablet in order to allow it to work in the small intestine. 
Clinical trials needed to have been carried out to substantiate these findings and gain 
confidence with this type of enzyme, but nevertheless, it opened the way for enzyme 
therapy for palliative care of coeliac patients. 
In more recent studies, the basic premise behind the alleviation of symptoms by the use of 
enzyme therapy is that the pathogenesis cannot occur if the gluten proteins are digested to 
amino-acids and very small peptides. It is well known that the collective amino acids 
which comprise gluten are not toxic to individuals with CD. After the large series of 
experiments which provided evidence for an enzyme deficiency in CD, the ability of 
porcine or bovine intestinal extracts to complete the digestion in vitro of peptic-tryptic-
pancreatinic digests of gliadin (from wheat gluten) was observed (Cornell and 
Stelmasiak,2004 ). 
A clinical trial to test the efficacy of these extracts in countering the effects of a modest 
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gluten challenge in patients with CD was conducted at the Royal Melbourne Hospital. 
Volunteers were 21 biopsy-proven adult volunteers who were on a gluten-free diet. The 
trial was of double-blind crossover design using a placebo and the enzyme extract in 
enterically-coated capsules. The results showed there were benefits in this type of enzyme 
therapy as symptoms were ameliorated in the vast majority of those patients who 
developed moderate-severe symptoms (Cornell et ai.,2005). In the 6 patients who were 
biopsied, histological examination showed that 5 showed abnormalities at the start of the 
trial, but that further damage as the result of the gluten-challenge was reduced by means of 
the intervention with enzyme extract. Antibodies to tTG and gliadin (Dahele et ai., 2001) 
were roughly correlated with the severity of histological damage, but there was no 
significant correlation in antibody titres with symptoms produced by the challenge across 
all patients, nor was there any significant reduction in antibody titres with enzyme therapy 
(Cornell et al,2005). However, it seems that a promising new approach to patient 
management is emerging, representing a new breakthrough after 50 years of sole treatment 
by a gluten-free diet. The enzyme extract will enable patients to gain the benefit of 
complete exclusion of gluten by functioning as a safeguard. 
6.Why enzyme therapy is successful 
The active enzymes in these animal intestinal extracts are able to digest the toxic peptides 
in a PTP digest of gliadin and reduce their deleterious effects. Their effectiveness can be 
measured by their ability to protect rat-liver lysosomes from the action ofPTP digests 
(Cornell and Townley, 1973 b). The substrates involved include the serine - and tyrosine-
containing peptides in the region of residues 6-19 and 75-86 respectively of A-gliadin, 
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but otber active fragments such as 31-49 would be included. When we look at peptide, 75-
86 (RPQQPYPQPQPQ), we notice it contains the QQPY motif ofthe toxic residual 
octapeptide 77-84 and the toxic peptide 31-49. Nonnal mucosal digestion of peptide 75-
86 reduces the amounts of residual peptides considerably and hence would lessen the 
consequential immunological reactions (Cornell, 1998). 
Witb regard to the serine-containing peptides, one of the most toxic is peptide 11-19 of A-
gliadin (QNPSQQQPQ). An enzyme which attacks the PSQQ motif appears to be missing 
in remission coeliac mucosa (Cornell and Rivett, 1995), but it is unknown whether it is the 
same enzyme that is required for digestion of the tyrosine peptides. The ability of both 
nonnal intestinal mucosa and animal intestinal eXtracts to detoxifY Fraction 9 (Cornell and 
Stelmasiak,2004) and peptic-tryptic digests of gluten indicates that such enzymes must be 
present in tbe animal intestinal extracts, a point not lost on Frazer et al. (1959). 
7.What type of enzyme is missing? 
Several early investigations reported tbe presence of specific peptidases, capable of 
splitting small peptides, in the cytoplasm and brush border of animal enterocytes ( Slaby 
et al.,1978).They found endopeptidase activity in the supernatant oftbe mucous 
membrane of human small intestine homogenised with Triton X-100. Splitting of 
oligopeptides can occur by stepwise deletion of amino acids, but there is now evidence to 
suggest that the motifs associated with toxicity are a barrier to attack (Cornell,2006). 
Assays ofbrush border and cytosol peptidase activities in the small intestine of coeliac 
patients revealed that Aminopeptidase A was the only significantly reduced peptidase 
----------------------------------------------
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activity in children with CD in remission, compared with control children ( Generoso et 
al.,1980).The substrate used here was u- glutamyl- ~- naphthylamide and the average 
values of enzyme activity were reduced to 70% of controls in 8 patients (p = 0.01). These 
experiments should perhaps be extended to include substrates that contain the 4-mer 
motifs associated with toxicity, otherwise there is only a small chance of finding the 
enzyme responsible for detoxification ofthe oligopeptides. 
The structure of peptide 75-86, with its five proline residues suggests the possibility of a 
prolyl endopeptidase as the missing enzyme in CD and the one present in the animal 
mucosal extracts. However, reports to date indicate only a limited role for this enzyme in 
the detoxification of gluten ( Matysiak-Budnik et al.,2005). Furthermore, no deficiency of 
this enzyme in remission coeliac mucosa has been detected (Donlon and Stevens,2004). 
There is still the likelihood of the enzyme being an endopeptidase required to attack 
motifs associated with toxicity, but it is most unlikely to be prolyl endopeptidase because 
this enzyme would be depleted in mucosa from remission coeliacs in remission. 
8.Conclusions 
There needs to be a more concentrated effort in diagnosis of CD, as the symptoms, 
particularly in adults, can be quite covert. This means that it is imperative to diagnose the 
disease in early childhood, as this also avoids the adverse psychological symptoms, which 
are apparent in some teenage children with untreated CD as well as the long term effects 
of malnutrition. The use of blood tests for determining levels of antibodies to tissue 
transglutaminaseis highly recommended, followed by biopsy of the small bowel. 
The use of enzyme therapy based on animal intestinal extracts is strongly suggested as a 
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safeguard, since despite better food labelling, it is still extremely difficult to maintain a 
strict gluten-free diet. A clinical trial has indicated that an encapsulated form of porcine 
intestinal extract is helpful in counteracting symptoms caused by modest amounts of 
gluten and should enable the small bowel to recover from traces of gluten accidentally 
ingested by patients trying to follow a gluten-free diet. 
A unified theory of CD now emerges where the aetiology ofthe disease is recognised as 
defective digestion of gluten, followed by immunological reactions and direct cytotoxicity 
resulting from the abnormally high concentrations of certain undigested peptides. Thus, 
for the disease to manifest itself, both the aetiology and pathogenesis are mutually linked 
and thus the term aetio-pathogenesis could be used to encapsulate the complex events 
leading to damage of the small intestine. The key defect in coeliac disease is probably a 
genetic one which prevents biosynthesis of certain peptidases and that individuals of DQ2 
and DQ8 haplotyping are the most susceptible. 
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